ANAVEX LIFE SCIENCES CORP.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and cash equivalents | $102.6M-22.4% | $132.2M-12.5% | $151.0M+1.3% | $149.2M |
| Incentive and tax receivables | $809K-67.0% | $2.4M-9.6% | $2.7M-15.2% | $3.2M |
| Prepaid expenses and other current assets | $429K-53.9% | $931K+42.6% | $653K+84.5% | $354K |
| Total Assets | $103.8M-23.4% | $135.6M-12.2% | $154.4M+1.1% | $152.7M |
| Accounts payable | $4.2M-55.9% | $9.6M+122.7% | $4.3M+13.0% | $3.8M |
| Accrued liabilities - Note 3 | $3.9M-19.5% | $4.8M-33.7% | $7.3M+22.7% | $5.9M |
| Deferred grant income - Note 4 | $805K-4.4% | $842K-8.2% | $917K+106.5% | $444K |
| Total Liabilities | $8.9M-41.5% | $15.3M+22.1% | $12.5M+22.7% | $10.2M |
| Capital stock Authorized: 200,000,000 common stock, par value $0.001 per share Issued and outstanding: 86,668,521 common shares (2024 - 84,795,517) | $87000.00+2.4% | $85000.00+3.7% | $82000.00+5.1% | $78000.00 |
| Additional paid-in capital | $477.2M+4.6% | $456.2M+4.9% | $434.8M+12.1% | $388.0M |
| Accumulated deficit | -$382.4M-13.8% | -$336.1M-14.7% | -$293.1M-19.3% | -$245.6M |
| Total Stockholders’ Equity | $94.9M-21.1% | $120.3M-15.2% | $141.9M-0.4% | $142.5M |
| Total Liabilities and Stockholders’ Equity | $103.8M-23.4% | $135.6M-12.2% | $154.4M+1.1% | $152.7M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
No Form 4 transactions on record.
Informational purposes only, not investment advice.